The Critical Path Institute: transforming competitors into collaborators

摘要

The Critical Path Institute brings scientists from regulatory agencies, industry and academia together to improve drug development and regulatory processes. Founded in 2005, the Critical Path Institute (C-Path) originates from the US Food and Drug Administration (FDA) s Critical Path Initiative, which a decade ago identified the need to connect scientific advancement with regulatory policy through public-private partnerships (PPPs). Today, the institute serves as a catalyst in the development of new approaches to advance medical innovation and regulatory science by leading teams that share data, knowledge and expertise to produce sound, consensus-based science.